Biological Therapy for Psoriatic Arthritis in Clinical Practice: Outcomes Up to 2 Years

Abstract

Anti-tumor necrosis factor-α therapy, often combined with conventional disease-modifying antirheumatic drugs, appeared to have limited toxicity and persistent effectiveness for up to 2 years in a cohort of Finnish patients with severe peripheral PsA.